About me
Christine Cassiano is the Executive Vice President, Chief Corporate Affairs and Brand Strategy Officer and one of the founding members of Allogene. Christine, who previously served as Chief Communications Officer at Allogene, is a communications executive with wide experience in investor relations, corporate communications, media relations, brand strategy and public affairs. Christine’s career is distinguished by the development of integrated communications strategies for companies with novel therapies such as YESCARTA® (axicabtagene ciloleucel) and BOTOX®/BOTOX® Cosmetic (onabotulinumtoxinA). Prior to Allogene, Christine served as Senior Vice President of Corporate Communications and Investor Relations for Kite until its acquisition by Gilead Sciences in 2017. Prior to that, she was the Head of Healthcare for W2O Group (now Real Chemistry). In 2012, Christine co-founded ARC2 Communications & Media, a boutique agency that developed groundbreaking platforms for some of the largest companies in healthcare. Before, she served as Senior Vice President and Co-Director, Healthcare, at Hill + Knowlton Strategies. Christine also held senior global communications roles in biotechnology and pharmaceutical companies, including Amgen, which also included an expatriate assignment in Switzerland overseeing all European communications, Allergan and Abraxis BioScience. Some of Christine’s career achievements include a SABRE Silver Anvil Award for the launch of BOTOX® Cosmetic (Allergan), an In2 SABRE Award for the Most Innovative Brand/Agency Collaboration (Pfizer/ARC2), and PR Week’s 40 Under 40. Christine serves as a Senior Strategic Advisor to Urogen Pharma and Vida Ventures. She holds a B.A. from California State University, Fullerton and Investor Relations Certification (IRC) from the University of California, Irvine.